L-asparaginase in the treatment of extranodal NK/T-cell lymphoma nasal-type

What is it about?

Extranodal natural killer/T-cell lymphoma, nasal-type (ENKTL) is a rare disease of non-Hodgkin’s lymphoma. ENKTL represents an aggressive clinical course and poor prognosis. The efficacy of conventional anthracycline-based regimens has been disappointed for ENKTL. Recently, a series of L-asparaginase-containing regimens have significantly improved the efficacy and prognosis for patients with ENKTL and confirmed the important role of L-asparaginase as an essential component in the treatment of ENKTL. The review "Clinical study of L-asparaginase in the treatment of extranodal NK/T-cell lymphoma nasal-type" published in Hematological Oncology focused on the pharmacokinetics of L-asparaginase preparations, the updated clinical study of a series of L-asparaginase-containing regimens in the treatment of ENKTL and future clinical study directions of L-asparaginase-containing regimens in ENKTL. Considering to early detect an unexpectedly premature asparaginase inactivation induced by antiasparaginase antibodies and switch to another L-asparaginase preparation as well as to individualize L-asparaginase dose or schedule, drug monitoring of L-asparaginase activity levels in plasma is important and needs further study in ENKTL. In order to further evaluate the efficacy of different L-asparaginase-containing regimens and to explore standard L-asparaginase-containing regimen, multicenter larger randomized clinical trials are warranted.

Featured Image